GlassScriptPhysician profile
Rand Naffouje
NPI 1124469267
$3,836.82
in general payments reported to CMS, 2019-2025
45 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $233 · 2021: $1,011 · 2022: $1,738 · 2023: $175 · 2024: $288 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.13 |
| Education | $107.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $317.60 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $268.83 | 2021-2024 | |
| Astellas Pharma US INC | $257.98 | 2019-2024 | Vyloy |
| Astrazeneca Pharmaceuticals LP | $251.55 | 2020-2024 | Calquence |
| Lilly USA, LLC | $219.39 | 2021-2024 | Verzenio, Jaypirca |
| Seagen INC. | $216.40 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $213.51 | 2021-2025 | Keytruda |
| Celgene Corporation | $197.10 | 2019-2022 | |
| Amgen INC. | $170.15 | 2020-2022 | |
| Pfizer INC. | $165.25 | 2021-2025 | |
| Gilead Sciences, INC. | $109.11 | 2022-2025 | Trodelvy |
| Janssen Biotech, INC. | $103.53 | 2022-2025 | Rybrevant |
| Incyte Corporation | $102.97 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $101.38 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $89.51 | 2020-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rand Naffouje listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.